Exagen Inc
NASDAQ:XGN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.85
11.96
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Gross Margin
Exagen Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Exagen Inc
NASDAQ:XGN
|
135.5m USD |
60%
|
|
| IL |
C
|
Can Fite Biopharma Ltd
TASE:CANF
|
707T ILS |
0%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
0%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
399.7B USD |
71%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
181.3B USD |
72%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
151.9B USD |
79%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
122.7B USD |
86%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
76%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
85.8B USD |
86%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
84.5B AUD |
52%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
55.7B USD |
84%
|
Exagen Inc
Glance View
Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company is headquartered in Vista, California and currently employs 219 full-time employees. The company went IPO on 2019-09-19. The firm offers physicians testing for patients and healthcare providers in diagnosis, prognosis, and monitoring of autoimmune conditions. The firm develops and commercialize testing products under the brand name AVISE. Its products include AVISE CTD, AVISE Lupus, AVISE APS, AVISE Vasculitis AAV, AVISE SLE Prognostic, AVISE Anti-CarP, AVISE PC4d, AVISE SLE Monitor and AVISE MTX. The firm's lead testing product AVISE enables diagnosis for patients with symptoms of connective tissue diseases (CTD) and Systemic lupus erythematosus (SLE). The Company’s AVISE brand allows for the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis (RA). The Company’s product portfolio integrates proprietary CB-CAPs technology, which is a stable and reliable method for differentially diagnosing systemic lupus erythematosus.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Exagen Inc's most recent financial statements, the company has Gross Margin of 59.9%.